Revive Therapeutics (TSE:RVV) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Revive Therapeutics has updated stakeholders on the progress of their lateral flow test kit for detecting long COVID, following guidance from the FDA to pursue a De Novo regulatory pathway, which requires a clinical study for potential approval. As there’s no FDA-approved clinical diagnosis for long COVID yet, the company has secured exclusive rights to novel blood biomarkers for the condition, aiming to address a critical need in post-COVID-19 healthcare.
For further insights into TSE:RVV stock, check out TipRanks’ Stock Analysis page.